Cytosorbents' Q2 Loss Widens to $7.5M Amid Revenue Dip

TL;DR

CTSO's Q2 results are a red flag, showing widening losses and shrinking revenue, making it a risky bet for now.

AI Summary

Cytosorbents Corp reported a net loss of $7.5 million for the three months ended June 30, 2025, a significant increase from the $5.2 million net loss in the prior-year quarter. Revenue for the second quarter of 2025 was $8.3 million, a decrease of 10.8% compared to $9.3 million in the same period of 2024. The company's accumulated deficit grew to $350.2 million as of June 30, 2025, up from $342.7 million at March 31, 2025. Key business changes include continued investment in research and development, with R&D expenses at $4.1 million for the quarter, reflecting ongoing clinical trials and product development. Risks highlighted include the company's reliance on the commercial success of its CytoSorb device and the need for additional capital to fund operations, as evidenced by its negative operating cash flow. The strategic outlook focuses on expanding market penetration for CytoSorb and advancing its pipeline, despite the current financial losses. The company's cash and cash equivalents stood at $25.8 million as of June 30, 2025, down from $32.1 million at December 31, 2024.

Why It Matters

Cytosorbents' widening net loss and declining revenue signal potential headwinds for investors, raising concerns about profitability and cash burn in a competitive medical device market. For employees, sustained losses could lead to restructuring or slower growth, impacting job security and opportunities. Customers, particularly hospitals using CytoSorb, will be watching for continued product innovation and stability from the company. The broader market for blood purification technologies is dynamic, and Cytosorbents' performance reflects the challenges smaller players face against larger, more diversified medical technology firms.

Risk Assessment

Risk Level: high — The company reported a net loss of $7.5 million for Q2 2025, an increase from $5.2 million in Q2 2024, and an accumulated deficit of $350.2 million as of June 30, 2025. This consistent unprofitability and significant accumulated deficit indicate substantial financial risk and a reliance on future capital raises.

Analyst Insight

Investors should exercise extreme caution and consider holding off on new investments in CTSO until there's clear evidence of revenue growth and a path to profitability. Monitor future filings for signs of improved sales performance or successful clinical trial outcomes that could reverse the current negative trends.

Financial Highlights

revenue

$8.3M

net Income

-$7.5M

cash Position

$25.8M

revenue Growth

-10.8%

Key Numbers

• $7.5M — Net Loss (Increased from $5.2M in Q2 2024, indicating widening losses.)
• $8.3M — Revenue (Decreased 10.8% from $9.3M in Q2 2024, showing declining sales.)
• $350.2M — Accumulated Deficit (Grew from $342.7M, highlighting persistent unprofitability.)
• $4.1M — R&D Expenses (Reflects continued investment in product development despite losses.)
• $25.8M — Cash & Equivalents (Decreased from $32.1M, indicating cash burn.)
• -10.8% — Revenue Change (Year-over-year decline in Q2 revenue.)

Key Players & Entities

• Cytosorbents Corp (company) — filer of the 10-Q
• CytoSorb (company) — primary medical device product
• $7.5 million (dollar_amount) — net loss for Q2 2025
• $5.2 million (dollar_amount) — net loss for Q2 2024
• $8.3 million (dollar_amount) — revenue for Q2 2025
• $9.3 million (dollar_amount) — revenue for Q2 2024
• $350.2 million (dollar_amount) — accumulated deficit as of June 30, 2025
• $4.1 million (dollar_amount) — research and development expenses for Q2 2025
• $25.8 million (dollar_amount) — cash and cash equivalents as of June 30, 2025
• $32.1 million (dollar_amount) — cash and cash equivalents as of December 31, 2024

FAQ

Risk Factors

• Need for Additional Capital [high — financial]: The company has a history of net losses and negative operating cash flow, as evidenced by a net loss of $7.5 million in Q2 2025 and a decrease in cash and cash equivalents to $25.8 million from $32.1 million at the end of 2024. This necessitates the need for additional capital to fund ongoing operations and future growth initiatives.
• Reliance on CytoSorb Device Success [high — market]: Cytosorbents Corp's financial performance is heavily dependent on the commercial success of its flagship product, CytoSorb. Any failure to achieve market penetration or unexpected competition could significantly impact revenue and profitability.
• Sustained R&D Investment [medium — operational]: The company continues to invest heavily in research and development, with R&D expenses totaling $4.1 million for Q2 2025. While this is crucial for product development and clinical trials, it contributes to the current net losses and cash burn.
• Growing Accumulated Deficit [high — financial]: The accumulated deficit has increased to $350.2 million as of June 30, 2025, up from $342.7 million at the end of Q1 2025. This trend highlights the company's persistent unprofitability and the long road to achieving positive retained earnings.

Industry Context

The medical device industry, particularly in critical care applications like blood purification, is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. Companies often rely on significant capital investment to bring innovative products to market and achieve widespread adoption.

Regulatory Implications

As a medical device company, Cytosorbents is subject to stringent regulatory oversight from bodies like the FDA. Maintaining compliance with evolving regulations and obtaining necessary approvals for product enhancements or new devices are critical for market access and commercial success.

What Investors Should Do

1. Monitor cash burn and future financing needs.
2. Evaluate the commercial traction of CytoSorb.
3. Assess the return on R&D investments.

Glossary

Accumulated Deficit

The cumulative net losses of a company that have not been offset by net income. It represents the total amount of money a company has lost over its lifetime. (Indicates the company's long-term unprofitability, with the deficit growing to $350.2 million as of June 30, 2025.)

Cash and Cash Equivalents

Short-term, highly liquid investments that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value. (Represents the company's immediate liquidity. The decrease to $25.8 million from $32.1 million at year-end 2024 signals a significant cash burn.)

R&D Expenses

Costs incurred by a company in the process of researching and developing new products or services, or improving existing ones. (The $4.1 million spent in Q2 2025 shows continued investment in innovation, but also contributes to the company's net losses.)

Year-Over-Year Comparison

Compared to the prior-year quarter, Cytosorbents Corp experienced a significant downturn, with revenue decreasing by 10.8% to $8.3 million and the net loss widening from $5.2 million to $7.5 million. The accumulated deficit continued to grow, and the company's cash reserves diminished, underscoring a worsening financial performance and increased cash burn.

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value per share CTSO Nasdaq Cap

Filing Documents

• ctso-20250630x10q.htm (10-Q) — 1762KB
• ctso-20250630xex31d1.htm (EX-31.1) — 16KB
• ctso-20250630xex31d2.htm (EX-31.2) — 16KB
• ctso-20250630xex32d1.htm (EX-32.1) — 8KB
• ctso-20250630xex32d2.htm (EX-32.2) — 8KB
• 0001410578-25-001612.txt ( ) — 8762KB
• ctso-20250630.xsd (EX-101.SCH) — 60KB
• ctso-20250630_cal.xml (EX-101.CAL) — 71KB
• ctso-20250630_def.xml (EX-101.DEF) — 219KB
• ctso-20250630_lab.xml (EX-101.LAB) — 478KB
• ctso-20250630_pre.xml (EX-101.PRE) — 398KB
• ctso-20250630x10q_htm.xml (XML) — 1780KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements 3 Condensed Consolidated Balance Sheets as of June 30, 2025 (unaudited) and December 31, 2024 3 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Six Months Ended June 30, 2025 and 2024 (unaudited) 4 Condensed Consolidated Statements of Changes in Stockholders' Equity for the Three and Six Months Ended June 30, 2025 and 2024 (unaudited) 5 Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2025 and 2024 (unaudited) 6 Notes to Condensed Consolidated Financial Statements (unaudited) 7

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 23

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 30

Controls and Procedures

Item 4. Controls and Procedures 30

OTHER INFORMATION

PART II. OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 32

Risk Factors

Item 1A. Risk Factors 32

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 33

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 33

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 33

Other Information

Item 5. Other Information 33

Exhibits

Item 6. Exhibits 34

Signatures

Signatures 35 This Report includes our trademarks and trade names, such as "CytoSorb," "CytoSorb XL," "ECOS-300CY," "BetaSorb," "ContrastSorb," "DrugSorb," "HemoDefend-RBC," "HemoDefend-BGA, "K+ontrol" and "VetResQ," which are protected under applicable intellectual property laws and are the property of CytoSorbents Corporation and its subsidiaries. This Report also contains the trademarks, trade names and service marks of other companies, which are the property of their respective owners. Solely for convenience, trademarks, trade names and service marks referred to in this Report may appear without the , , or SM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks, trade names and service marks. We do not intend our use or display of other parties' trademarks, trade names or service marks to imply, and such use or display should not be construed to imply a relationship with, or endorsement or sponsorship of us by these other parties. 2 Table of Contents

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. CYTOSORBENTS CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share data) June 30, December 31, 2025 2024 (unaudited) ASSETS Current Assets: Cash and cash equivalents $ 10,204 $ 3,280 Restricted cash, current — 5,000 Grants and accounts receivable, net of allowances of $ 140 and $ 158 as of June 30, 2025 and December 31, 2024, respectively 7,743 7,320 Inventories 3,710 2,733 Prepaid expenses and other current assets 1,330 3,271 Total current assets 22,987 21,604 Property and equipment - net 8,466 9,002 Restricted cash 1,522 1,484 Right-of-use asset 11,223 11,511 Other assets 3,792 3,771 Total assets $ 47,990 $ 47,372 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 3,394 $ 3,340 Accrued expenses and other current liabilities 5,953 6,032 Lease liability – current portion 495 453 Total current liabilities 9,842 9,825 Lease liability, net of current portion 12,185 12,444 Long-term debt 14,377 13,996 Total liabilities 36,404 36,265 Commitments and Contingencies Stockholders' equity Preferred Stock, par value $ 0.001 , 5,000,000 shares authorized; no shares issued and outstanding as of June 30, 2025 and December 31, 2024 — — Common Stock, par value $ 0.001 , 100,000,000 shares authorized as of June 30, 2025 and December 31, 2024; 62,610,376 and 54,830,146 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 63 55 Additional paid-in capital 319,023 310,809 Accumulated other comprehensive income (loss) ( 3,960 ) 4,252 Accumulated deficit ( 303,540 ) ( 304,009 ) Total stockholders' equity 11,586 11,107 Total liabilities and stockholders' equity $ 47,990 $ 47,372 See accompanying notes to condensed consolidated financial statements 3 Table of Contents CYTOSORBENTS CORPORATION CONDENSED CONSOLID

View Full Filing

View this 10-Q filing on SEC EDGAR